Related coverage linked through entity extraction aliases.
Apr 01, 2026
The liposomal doxorubicin market is projected to grow from $1.32 billion in 2025 to $1.77 billion by 2030, while the broader breast cancer drugs market is expected to reach $54.49 billion by 2036. Growth is driven by increasing cancer incidence, adoption of targeted therapies, and advancements in drug delivery systems including liposomal formulations and antibody-drug conjugates.
Apr 01, 2026
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Mar 29, 2026
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
Mar 26, 2026
Orphan drug sales are projected to reach $400 billion by 2032, accounting for over 21% of prescription drug sales. Recent policy changes expanded IRA exemptions for multi-indication orphan drugs and reauthorized pediatric review vouchers. Johnson & Johnson's Darzalex leads orphan drug sales with $31 billion projected revenue.
Mar 25, 2026
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
Mar 23, 2026
The FDA has approved a monthly subcutaneous dosing schedule for Johnson & Johnson's Rybrevant Faspro for EGFR-mutated NSCLC, based on PALOMA-2 trial data showing 82-87% response rates. The approval follows the drug's initial biweekly dosing approval in December 2025 and offers reduced administration time and reactions compared to intravenous delivery.
Mar 23, 2026
The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.
Mar 17, 2026
Johnson & Johnson settled two cosmetic talc cases in March 2026, one before jury selection in Florida and another after opening statements in Washington, as the company faces multiple trials scheduled for April.
Mar 17, 2026
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Mar 06, 2026
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
Mar 05, 2026
Protagonist Therapeutics reported fourth quarter and full year 2025 financial results, with two NDAs submitted and multiple Phase 3 trials advancing. The company holds $646 million in cash and expects regulatory decisions in 2026.
Mar 04, 2026
The immuno-oncology market is projected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, driven by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, with North America commanding 43% market share.
Mar 03, 2026
Johnson & Johnson announced a $1 billion cell therapy manufacturing facility in Pennsylvania while reportedly exploring a sale of its DePuy Synthes orthopedics business for over $20 billion.
Feb 28, 2026
Johnson & Johnson stock hit an all-time high of $246.54, up 54.05% over the past year. The company announced a $1 billion investment in a Pennsylvania cell therapy facility and received upgraded price targets from major financial firms.
Feb 27, 2026
Pharmaceutical companies are increasingly partnering with biotechs developing RNA-targeting small molecules, driven by advances in RNA structural biology and the success of drugs like Roche's Evrysdi. The approach aims to address "undruggable" targets while offering oral availability advantages.
Feb 26, 2026
Researchers at Stanford and Harvard are developing nasal spray vaccines offering broad protection against respiratory infections, with early animal and phase 1 human trials showing safety and potential efficacy.
Feb 20, 2026
Johnson & Johnson announced a more than $1 billion investment to build a new cell therapy manufacturing facility in Lower Gwynedd, Pennsylvania, creating 500 skilled biomanufacturing jobs and 4,000 construction jobs as part of its $55 billion U.S. investment strategy through early 2029.
Feb 25, 2026
The global pharmaceutical market reached nearly $1.7 trillion in value, with Johnson & Johnson leading prescription sales at approximately $55.8 billion while Merck & Co. topped research and development investment at $17.8 billion.
Feb 20, 2026
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
Feb 25, 2026
The FDA has approved a new monthly dosing schedule for Johnson & Johnson's Rybrevant Faspro combined with Lazcluze for first-line treatment of advanced EGFR-mutated non-small cell lung cancer, allowing patients to transition to monthly dosing as early as week five.
